Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2564901rdf:typepubmed:Citationlld:pubmed
pubmed-article:2564901lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2564901lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:2564901lifeskim:mentionsumls-concept:C0262926lld:lifeskim
pubmed-article:2564901lifeskim:mentionsumls-concept:C0332119lld:lifeskim
pubmed-article:2564901lifeskim:mentionsumls-concept:C0175860lld:lifeskim
pubmed-article:2564901lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:2564901lifeskim:mentionsumls-concept:C0392752lld:lifeskim
pubmed-article:2564901pubmed:issue8642lld:pubmed
pubmed-article:2564901pubmed:dateCreated1989-5-18lld:pubmed
pubmed-article:2564901pubmed:abstractTextIn a population-based study, disease progression and survival were evaluated in untreated patients with newly diagnosed cancer of the prostate without distant metastases. Complete follow-up was achieved in 223 of 227 (98%) consecutively diagnosed, eligible patients of all ages. After 5 years, the cumulative progression-free survival (with 95% confidence interval) was 71.8 (65.5-78.1)% and survival corrected for causes of death other than prostatic cancer was 93.8 (88.3-97.6)%. Univariate and multivariate analyses showed no association between age at diagnosis and the natural course. Local progression was less common in localised, non-palpable tumours than in larger tumours. The rate of progression was 18.7 (6.1-57.1) times higher and that of disease-specific death 216.0 (31.2-1496) times higher in patients with poorly than in those with highly differentiated tumours. It is concluded that tumour grade at diagnosis is an excellent predictor of local and distant progression. The low death rate, especially in patients with highly and moderately differentiated tumours, means that any local or systemic therapy intended for patients with early prostatic cancer must be evaluated in clinical trials with untreated controls for comparison.lld:pubmed
pubmed-article:2564901pubmed:languageenglld:pubmed
pubmed-article:2564901pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2564901pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2564901pubmed:statusMEDLINElld:pubmed
pubmed-article:2564901pubmed:monthAprlld:pubmed
pubmed-article:2564901pubmed:issn0140-6736lld:pubmed
pubmed-article:2564901pubmed:authorpubmed-author:BergströmRRlld:pubmed
pubmed-article:2564901pubmed:authorpubmed-author:JohanssonJ...lld:pubmed
pubmed-article:2564901pubmed:authorpubmed-author:AdamiH OHOlld:pubmed
pubmed-article:2564901pubmed:authorpubmed-author:KraazWWlld:pubmed
pubmed-article:2564901pubmed:authorpubmed-author:AnderssonS...lld:pubmed
pubmed-article:2564901pubmed:authorpubmed-author:KrusemoU BUBlld:pubmed
pubmed-article:2564901pubmed:issnTypePrintlld:pubmed
pubmed-article:2564901pubmed:day15lld:pubmed
pubmed-article:2564901pubmed:volume1lld:pubmed
pubmed-article:2564901pubmed:ownerNLMlld:pubmed
pubmed-article:2564901pubmed:authorsCompleteYlld:pubmed
pubmed-article:2564901pubmed:pagination799-803lld:pubmed
pubmed-article:2564901pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:meshHeadingpubmed-meshheading:2564901-...lld:pubmed
pubmed-article:2564901pubmed:year1989lld:pubmed
pubmed-article:2564901pubmed:articleTitleNatural history of localised prostatic cancer. A population-based study in 223 untreated patients.lld:pubmed
pubmed-article:2564901pubmed:affiliationDepartment of Urology, Orebro Medical Center, Sweden.lld:pubmed
pubmed-article:2564901pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2564901pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2564901pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:2564901pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2564901lld:pubmed